BNP-guided therapy of chronic heart failure: what is the evidence?
|Published in||Revue médicale suisse. 2009, vol. 5, no. 221, p. 2028-30, 2032-2033|
|Abstract||The use of biomarkers, such as type B natriuretic peptide (BNP, NT pro-BNP) to finely tune the treatment during the follow-up of patients with chronic heart failure is under investigation. The few existing studies published up to now suggest that this approach leads to fewer hospital readmissions and a lower mortality due to heart failure, except in patients over 75 years of age. The positive effects of the use of biomarkers seem to be due to a greater use of target doses of the medications recommended in heart failure (angiotensin converting enzyme, angiotensin receptor blockers, or beta-blockers) and to a better adhesion to guidelines. Thus, it may prove more efficient to develop efforts to increase physicians' adhesion to guidelines than to rely on the dosage of a biomarker.|
|Keywords||Aged — Chronic Disease — Follow-Up Studies — Heart Failure — Humans — Middle Aged — Natriuretic Peptide, Brain|
This document has no fulltext available yet, but you can contact its author by using the form below.
|COPT, Christophe, NENDAZ, Mathieu. BNP-guided therapy of chronic heart failure: what is the evidence?. In: Revue médicale suisse, 2009, vol. 5, n° 221, p. 2028-30, 2032-2033. https://archive-ouverte.unige.ch/unige:9580|